Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2023-02-01 00:00:00 ET · period of report 2023-01-30 · accession 0001209191-23-005996 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-01 | 2023-01-30 | ELVN | GRAY MICHAEL | CFO, COO | S - Sale | $3.92 | -3,596 | 37.5K | -9% | -$14.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-30 | S | D | 3,596 | $3.92 | 37,466 | D | — | — |